Simultaneous Effects of Viral Factors of Human Papilloma Virus and Epstein-Barr Virus on Progression of Breast and Thyroid Cancers: Application of Structural Equation Modeling.
Adult
Aged
Aged, 80 and over
Breast Neoplasms
/ etiology
Carcinoma, Ductal, Breast
/ etiology
Carcinoma, Lobular
/ etiology
Case-Control Studies
Disease Progression
Epstein-Barr Virus Infections
/ complications
Female
Follow-Up Studies
Herpesvirus 4, Human
/ isolation & purification
Humans
Latent Class Analysis
Male
Middle Aged
Papillomaviridae
/ isolation & purification
Papillomavirus Infections
/ complications
Prognosis
Thyroid Neoplasms
/ etiology
Viral Proteins
/ genetics
Epstein-Barr Virus
Human papilloma virus
Inflammation
Thyroid cancer
breast cancer
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 May 2020
01 May 2020
Historique:
received:
26
01
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
3
2
2021
Statut:
epublish
Résumé
This study aimed to assess effects of the sets of EBV and HPV expressed proteins simultaneously on the sets of cellular/inflammatory factors in breast and thyroid cancers using structural equation modeling. In this multi-center case-control study, according to the inclusion and exclusion criteria, 83 breast and 57 thyroid specimens were collected from the eligible patients. In addition, 31 and 18 histopathological evaluated normal breast and thyroid samples were also examined as age-matched healthy controls. In addition, ELISA and Real-time PCR were used to measure the expression level of viral and cellular/inflammatory genes and proteins. Structural equation modeling was used to test the causal associations between the sets of EBV and HPV expressed proteins with inflammatory factors in breast and thyroid cancers development. Breast cancer patients had a higher incidence of HPV-positively and EBV-positively than healthy controls (OR=1.66, 95%CI=0.79-3.47, P-value=0.177), (OR=3.18, 95%CI=1.52-6.63, P-value=0.002), respectively. In addition, thyroid cancer patients had a significantly higher incidence of EBV-positivity than healthy controls (OR=3.72, 95% CI=1.65-8.36, P-value=0.001). After fitting the SEM model, HPV proteins factor has significant direct and total effects on the cellular/inflammatory factors in breast cancer (direct effect: β=0.426, P-value=0.01; total effect: β=0.549, P-value<0.001). However, EBV proteins factor has most significant total effect on the cellular/inflammatory factors in breast cancer (total effect: β=0.804, P-value<0.001) than the cellular/inflammatory factors in thyroid cancer (total effect: β=0.789, P-value<0.001). For the first time, a significant association between EBV and HPV -genes, anoikis resistance and the development of breast and thyroid cancers demonstrated by using SEM, Simultaneously.<br />.
Identifiants
pubmed: 32458652
doi: 10.31557/APJCP.2020.21.5.1431
pmc: PMC7541891
pii:
doi:
Substances chimiques
Viral Proteins
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1431-1439Références
Cell Host Microbe. 2014 Mar 12;15(3):295-305
pubmed: 24629336
J Gen Virol. 2006 Oct;87(Pt 10):2885-2890
pubmed: 16963746
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Annu Rev Clin Psychol. 2005;1:31-65
pubmed: 17716081
Virol J. 2011 Sep 25;8:453
pubmed: 21943319
BMC Cancer. 2014 Sep 11;14:665
pubmed: 25213133
Nat Rev Cancer. 2002 May;2(5):342-50
pubmed: 12044010
Otolaryngol Pol. 2014 Sep-Oct;68(5):213-9
pubmed: 25283316
J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6
pubmed: 12488476
Med Hypotheses. 2014 Jun;82(6):700-2
pubmed: 24685109
Cancer. 2002 Apr 15;94(8):2199-210
pubmed: 12001118
BMC Cancer. 2019 Jan 14;19(1):61
pubmed: 30642295
Updates Surg. 2017 Sep;69(3):313-317
pubmed: 28260181
N Engl J Med. 1991 Jan 3;324(1):1-8
pubmed: 1701519
J Virol Methods. 2008 Jan;147(1):26-36
pubmed: 17870188
J Virol. 2009 Aug;83(15):7749-60
pubmed: 19439479
Oncol Lett. 2016 Mar;11(3):1635-1644
pubmed: 26998055
Tumour Biol. 2017 Jun;39(6):1010428317703634
pubmed: 28618936
Cancer Res Treat. 2005 Dec;37(6):319-24
pubmed: 19956366
Oncol Lett. 2015 Mar;9(3):1015-1026
pubmed: 25663851
J Gen Virol. 2008 Nov;89(Pt 11):2806-2820
pubmed: 18931079
Med Hypotheses. 2009 Aug;73(2):184-6
pubmed: 19361933
PLoS One. 2015 Feb 27;10(2):e0118989
pubmed: 25723522
J Clin Endocrinol Metab. 1996 Mar;81(3):990-4
pubmed: 8772562
Cell Mol Biol Lett. 2009;14(2):222-47
pubmed: 19082921
J Cell Physiol. 2019 Apr;234(4):3790-3799
pubmed: 30362517
Cancer Lett. 2001 Apr 26;165(2):219-24
pubmed: 11275372
J Biol Chem. 2000 Jan 7;275(1):87-94
pubmed: 10617590
J Interferon Cytokine Res. 2015 Jan;35(1):1-16
pubmed: 25068787
PLoS One. 2012;7(1):e28776
pubmed: 22242150
Blood. 1999 Jun 1;93(11):3949-55
pubmed: 10339504
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Immun Inflamm Dis. 2014 Aug;2(2):63-75
pubmed: 25400927
Cancer. 2001 Jul 15;92(2):225-31
pubmed: 11466673
J Biol Chem. 2005 Sep 30;280(39):33165-77
pubmed: 15983032
J Pathol. 2013 Nov;231(3):367-77
pubmed: 23934731
Br J Cancer. 2005 Oct 17;93(8):946-8
pubmed: 16222323
Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37
pubmed: 16931107
ChemMedChem. 2014 Jun;9(6):1286-93
pubmed: 24803138
Int J Cancer. 2006 Jun 15;118(12):3030-44
pubmed: 16404738
Hum Pathol. 2003 Nov;34(11):1170-7
pubmed: 14652819
Genes Dev. 2000 Dec 1;14(23):3065-73
pubmed: 11114894